文献速递贫血与红细胞疾病白血病

Darovasertib联合克唑替尼一线治疗转移性葡萄膜黑色素瘤:OptimUM-01研究的总生存、疗效与安全性

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study.
PubMed 文献 · J Clin Oncol · 2026-10-28

OptimUM-01是一项I/II期多中心开放标签剂量递增和扩展研究,评估darovasertib联合克唑替尼一线治疗44例初治转移性葡萄膜黑色素瘤患者。结果显示客观缓解率34.1%,中位无进展生存期7.0个月(95% CI 5.0-8.3),中位总生存期21.1个月(95% CI 11.9-20.7),安全性可控。

要点

  • Darovasertib联合克唑替尼一线治疗mUM的ORR为34.1%,DCR为90.2%。
  • 中位PFS为7.0个月(95% CI 5.0-8.3),中位OS为21.1个月(95% CI 11.9-20.7)。
  • 常见≥3级不良事件为肺栓塞(9.1%)和缺铁性贫血(6.8%)。

核心结论

  • Darovasertib联合克唑替尼在初治mUM中显示出令人鼓舞的疗效和可控的安全性,可能成为首创的靶向治疗选择。

研究设计与样本

  • OptimUM-01是一项I/II期、多中心、开放标签、剂量递增和扩展研究,纳入44例初治mUM患者。
  • 治疗方案为darovasertib 300 mg每日两次联合克唑替尼200 mg每日两次。
  • 入组标准包括GNAQ/11突变、RECIST v1.1可测量病灶、ECOG评分0-1及器官功能充足。

主要发现

  • 最常见不良事件为腹泻(95.2%)、恶心(84.1%)、外周水肿(61.4%)和呕吐(52.3%)。
  • ≥3级不良事件最常见为肺栓塞(9.1%)和缺铁性贫血(6.8%)。
  • 导致停药的不良事件发生于3例患者(6.8%)。
  • ORR为34.1%,DOR为9.0个月,8周时DCR为90.2%。
  • 中位PFS为7.0个月(95% CI 5.0-8.3),中位OS为21.1个月(95% CI 11.9-20.7)。

临床怎么用

  • 对于初治mUM患者,darovasertib联合克唑替尼可作为潜在的一线靶向治疗选择。
  • 治疗期间需关注腹泻、恶心、外周水肿等常见不良事件及肺栓塞、贫血等≥3级事件。

局限性

  • 本研究为II期扩展分析,样本量有限(44例),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastatic uveal melanoma (mUM) has poor prognosis with limited therapies. GNAQ/11 mutations that activate protein kinase C (PKC) are detected in 95% of UM tumors. Darovasertib is a first-in-class, oral, targeted PKC inhibitor that, in combination with the MET inhibitor crizotinib, has shown responses and encouraging survival outcomes in early mUM clinical trials. Here, we present phase 2 results in first-line patients with mUM treated with darovasertib 300 mg twice a day and crizotinib 200 mg twice a day. METHODS: The OptimUM-01 study was a phase I/II, multicenter, open-label, dose escalation and expansion study of darovasertib in patients with solid tumors harboring GNAQ/11 mutations irrespective of human leukocyte antigen status; this analysis focuses on the phase II expansion in previously untreated patients with mUM. Eligibility criteria included Response Evaluation Criteria in Solid Tumors v1.1 measurable disease, Eastern Cooperative Oncology Group performance status 0-1, and adequate organ function. Study end points included safety, objective response rate (ORR), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). RESULTS: Overall, 44 treatment-naïve patients were enrolled. The most common adverse events (AEs) were diarrhea (95.2%), nausea (84.1%), peripheral edema (61.4%), and vomiting (52.3%). The most common grade 3 or greater AEs were pulmonary embolism (9.1%) and iron deficiency anemia (6.8%). AEs leading to discontinuation occurred in three patients (6.8%). ORR was 34.1%, DOR was 9.0 months, and DCR was 90.2% at 8 weeks. The median PFS and OS were 7.0 months (95% CI, 5.0 to 8.3) and 21.1 months (95% CI, 11.9 to 20.7), respectively. CONCLUSION: Results from OptimUM-01 suggest that the combination of darovasertib and crizotinib has encouraging efficacy with a manageable safety profile and may represent a first-in-class targeted treatment option for patients with previously untreated mUM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McKean, Chmielowski, Butler, et al. Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study. J Clin Oncol. 2026. PMID: 42950186. doi:10.1200/JCO-26-00802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。